|
PF-23427 |
RIMACTAZID PAED 60/60 INTERMITTENT, Tabletas Masticables. |
2005-10-31 |
|
Sandoz GmbH |
Sudáfrica
|
Amicelco |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-23780 |
RIMCURE PAED 3-FDC Tabletas Masticables. |
2006-02-05 |
|
Agencias J.i. Cohen |
Sudáfrica
|
Amicelco |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-12013 |
Rabipur 2.5 UI inyectable |
2002-10-13 |
|
Hoechst Marion Roussel |
Guatemala
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-41695 |
AGRIPPAL S1 Suspensión inyectable |
2018-10-23 |
|
Novartis Vaccines Influenza S.r.l. |
Italia
|
Novartis Farmacéutica, Sociedad Anónima (América Central) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-44186 |
ESTRADOT 50 mcg/DIA Parche transdérmico |
2020-02-18 |
|
Novartis Pharma AG |
Estados Unidos de América
|
Novartis Farmacéutica, Sociedad Anónima (América Central) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29179 |
ESTRADOT 37.5 ug/dia, parche transdermico |
2007-10-31 |
|
Novartis Pharmaceuticals Corporation |
Estados Unidos de América
|
Novartis Farmaceutica S.A. (ac) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29180 |
ESTRADOT 50 ug/dia, parche transdermico |
2007-10-31 |
|
Novartis Pharmaceuticals Corporation |
Estados Unidos de América
|
Novartis Farmaceutica S.A. (ac) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29181 |
ESTRADOT 100 ug/dia, parche transdermico |
2007-10-31 |
|
Novartis Pharmaceuticals Corporation |
Estados Unidos de América
|
Novartis Farmaceutica S.A. (ac) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29182 |
ESTRADOT 75 ug/dia, parche transdermico |
2007-10-31 |
|
Novartis Pharmaceuticals Corporation |
Estados Unidos de América
|
Novartis Farmaceutica S.A. (ac) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-29804 |
Estalis 50/140 parches transdermicos |
2008-02-17 |
|
Novartis Pharmaceuticals Corporation |
Estados Unidos de América
|
Novartis Farmaceutica S.A. (ac) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|